Profit

Lupin Launches Hyperphosphatemia Treatment Capsules in US

 Share
EMAIL
PRINT
COMMENTS
New Delhi: Lupin has launched calcium acetate capsules, used in treating hyperphosphatemia in end stage renal failure, in the United States after receiving approval from the US Food and Drug Administration (FDA).

Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched calcium acetate capsules having received final approval from the US health regulator, the company said in a statement.

The Mumbai-based firm's product is the generic version of Fresenius Medical Care North America's PhosLo Gelcaps.

The drug is indicated for the control of hyperphosphatemia in end stage renal failure.

As per IMS sales data, PhosLo Gelcaps had annual US sales of $54.5 million.

Shares in Lupin, on Monday, ended 1.25 per cent lower at Rs 2,053.40 apiece on the BSE, whose benchmark Sensex index finished down 0.4 per cent.


Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.

NDTV Beeps - your daily newsletter

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

Top